Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

PIN Pharma

PIN Pharma
PRIVATE STATUS
Series A LATEST DEAL TYPE
$6.75M LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of precision immune stimulants intended to link the innate and adaptive immune systems. The company's precision immune stimulants target at breast and colon cancer to overcome cancer-mediated immune suppression, enabling physicians to treat in an enhanced way.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 3960 Broadway
  • Suite 620
  • New York, NY 10032
  • United States

+1 (212) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore PIN Pharma’s full profile, request a free trial.

PIN Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 01-Jan-2012 $6.75M 00.000 000.00 Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

PIN Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00 00 00 00 00 000
To view this company’s complete Cap Table, request access »

PIN Pharma Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
NGN Capital Venture Capital Minority 000 0000 000000 0
Partnership for New York City Venture Capital Minority 000 0000 000000 0

PIN Pharma Executive Team (3)

Name Title Board
Seat
Contact
Info
Colin Bier Ph.D Chief Executive Officer, Chief Scientific Officer & President
Mark Smith Corporate Secretary, Chief Business Officer, Chief Finance Officer & Business Development Executive
Kenneth Gorelick MD Chief Medical Officer

PIN Pharma Board Members (2)

Name Representing Role Since Contact
Info
Ivica Cerina Ph.D NGN Capital Board Member 000 0000
William Gedale JD NGN Capital Chairman 000 0000